Use of antiretroviral drugs for prevention of HIV by blood donors has been documented in the United States [10], and should suboptimal adherence or “on demand” PrEP use result in breakthrough infections followed by partial or complete viral suppression, the potential exists for infectious blood products to be released if both serological and NAT screenings fail. The gene discussed is BRD2; the disease is infection.